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ABSTRACT Necrolytic migratory erythema is considered an obligatory cu-
taneous paraneoplastic sign associated with glucagonoma. Glucagonoma 
syndrome is defined by the presence of an alpha-cell secreting tumor of 
the pancreas, elevated levels of glucagon, and a characteristic rash called 
necrolytic migratory erythema. Although necrolytic migratory erythema is 
a specific finding in glucagonoma syndrome, it may occur in other settings, 
unassociated with an alpha-cell pancreatic tumor (pseudoglucagonoma 
syndrome). The rarity of glucagonoma imposes a challenge, with most pa-
tients being diagnosed after a long period of treatment for their skin rash. 
The main prognostic sign of glucagonoma are the subsequent metastases 
that come late in the course of the disease. Herein, we present a 55-year-
old female patient with a 5-year history of unrecognized cutaneous and 
systemic manifestations of glucagonoma syndrome. Based on the investi-
gations, the diagnosis of glucagonoma syndrome without metastases was 
established. After surgical removal of pancreatic carcinoma/glucagonoma, 
complete healing and a long disease-free period was achieved. Appropri-
ate awareness of the characteristics of necrolytic migratory erythema in 
physicians/dermatologists often leads to an early diagnosis of glucagono-
ma syndrome and enhances the chances of a favorable outcome.
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INTRODUCTION
The first association between a cutaneous rash 
and pancreatic neoplasm was observed in 1942 by 
Becker et al. (1). In 1973 Wilkinson defined the term 
“necrolytic migratory erythema” to describe the dis-
tinctive rash (2). Mallinson et al. (3) coined the term 
“glucagonoma syndrome”, a rare paraneoplastic phe-
nomenon in patients with necrolytic migratory ery-
thema, glucagonoma, and weight loss.
Glucagonoma is an extremely rare, slow-growing, 
frequently malignant neuroendocrine tumor of the 
alpha-cells of the pancreas, whereby abundant gluca-
gon is secreted. Estimated incidence is 1/20,000,000/
year (4). It typically presents with glucagonoma syn-
drome (GS). 
Necrolytic migratory erythema (NME) is consid-
ered a hallmark clinical sign of glucagonoma syn-
drome, present in approximately 70% of patients (5).
Considered an obligatory paraneoplastic sign, 
NME can be observed in the absence of glucagono-
ma in so called pseudoglucagonoma syndrome (6). 
In this condition, levels of glucagon are commonly 
elevated due to another disease of non-pancreatic 
origin, such as intestinal malabsorption disorders, cir-
rhosis, inflammatory bowel disease, pancreatitis, and 
other malignancies (7,8). 
Clinically, NME is distinctive, pruritic, bullous der-
matosis that evolves over a 2-week period and has a 
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cyclic course with spontaneous remissions and exac-
erbations. Individual lesions are pruritic and painful, 
initially appearing as erythematous vesicles and bul-
lae that evolve into patches or plaques with irregular 
borders, scaling, and crusting, sometimes with an ec-
zematous and psoriasiform appearance as they fade. 
Such a clinical aspect can mimic inverse psoriasis, ec-
zema, intertrigo, contact dermatitis, seborrheic der-
matitis and even pemphigus (4,9). After the vesicles 
and bullae rupture, they spread outward with crust-
ing and postinflammatory, residual hyperpigmenta-
tion. The distribution may be widespread or isolated 
to the perioral region, trunk, buttocks, groin, interglu-
teal region, genital area, lower extremities, palms, or 
fingers. It preferentially forms in intertriginous areas 
and pressure points; it can also form in areas of trau-
ma, a response pattern known as “koebnerization”. 
Glossitis, angular cheilitis, and stomatitis are associ-
ated mucosal manifestations. Diffuse alopecia and 
brittle nails can be observed. Skin changes appear 
early in the course of GS and are reason for seeking 
medical help for the first time. They are followed by 
systemic symptoms such as weight loss, diarrhea, di-
abetes mellitus, neuropsychiatric disorders, anemia, 
and thrombosis. 
We report a case of female patient with a 5-year 
history of cutaneous rash and systemic symptoms 
consistent with GS, without liver metastases. She was 
successfully operated on with a subsequent long dis-
ease-free period. This case is an example of the well-
established association between NME and GS and 
also emphasizes the importance of early detection of 
pancreatic carcinoma and prevention of its fatal me-
tastases.
CASE REPORT
A 55-year-old woman presented to the dermatolo-
gist complaining of a erythematous pruritic skin rash 
of a 5-year duration. The skin rash tended to occur 
in recurrent crops that later blistered and sloughed 
while new lesions occurred in another area. She also 
reported a painful, red, shiny smooth tongue, perioral 
rhagades, anorexia, insomnia, diarrhea (sporadically), 
and significant weight loss in the last year. Her family 
history was negative for endocrine disorders. 
Physical examination revealed an annular-circi-
nate, erythematous, scaly rash with areas of hyper-
pigmentation and skin sloughing, mainly involving 
the extremities, buttocks, and perineum. The lesions 
were highly suggestive of NME. Her tongue was atro-
phic and bright red (glossitis), and cheilitis angularis 
was visible. Severe cachexia was registered (36 kg/150 
cm) (Figure 1).
Skin biopsy from the lesion showed psoriasiform 
hyperplasia of the epidermis with overlying parakera-
tosis, slight spongiosis, subcorneal spongiform pus-
tules, and rare necrotic spinous cells. Discrete superfi-
cial perivascular infiltrate of lymphocytes and neutro-
phils was present in the papillary dermis. (Figure 2).
Laboratory investigations had the following re-
sults: elevated sedimentation rate (70/100); serum 
glucose, liver function tests, plasma proteins, en-
zymes, and electrolytes were all normal, but normo-
chromic-normocytic anemia and hyperglucagone-
Figure 1. Necrolytic migratory erythema: angular cheilitis, 
glossitis; multiple, annular, circinate, erythematous patches 
with superficial scaling at the borders involving the thighs, 
buttocks, palms, perineum, genital area, groin, and lower 
abdomen. 
Figure 2. Histopathology of the skin lesion (hematoxy-
lin and eosin): parakeratosis, psoriasiform epidermis with 
slight spongiosis, subcorneal spongiform pustules, and 
rare necrotic spinous cells. Discrete superficial perivascular 
dermal infiltrate of lymphocytes and neutrophils.
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mia were found. Glucagon level assay (EDTA-plasma) 
in two plasma samples taken during two separate ex-
acerbations of skin rash showed elevated values: 386 
ng/L; 290 ng/L; (normal range for adults 70-160 ng/L). 
Kidney function tests were normal.
Abdominal ultrasound revealed a hypoechogenic 
mass in the tail of the pancreas. Accordingly, contrast-
enhanced magnetic resonance imaging (MRI) in T1 
and T2 pulse sequences was performed. The coronal 
T1-weighted magnetic image of the upper abdomen 
confirmed the presence of a low intensity abnormal-
ity in the tail of the pancreas. The coronal T2-weighted 
image of abdomen, after IV-applied contrast, showed 
that the described abnormality had a tendency to be 
hyperintensive. The tumor mass was depicted as a 
high-intensity abnormality (3.0 cm × 2.5 cm) in the tail 
of the pancreas, lying at the splenic hilum (Figure 3).
The first pancreatic surgery was unsuccessful, and 
the patient underwent a second surgery in which the 
tumor was successfully removed (distal pancreatec-
tomy with splenectomy). Three months after the op-
eration, glucagon levels were reduced to normal (86 
ng/L) and the skin rash disappeared. Healing resulted 
in transitory residual hyperpigmentation. Histopath-
ological examination confirmed the diagnosis of a 
pancreatic neuroendocrine tumor. During 7-year fol-
low-up the patient has been completely disease-free 
and in excellent health.
DISCUSSION
GS is an extremely rare condition with an esti-
mated annual incidence of 1/20,000,000 (4). Conse-
quently, only a few surgeons and physicians will be 
faced with this peculiar diagnosis. Diagnosis of GS is 
based on clinical findings that include NME, elevated 
serum levels of glucagon, and an underlying islet-cell 
tumor within the pancreas that is secreting glucagon. 
All these criteria were fulfilled in the presented case. 
The major diagnostic criteria of GS are: imaging study 
confirming presence of pancreatic tumor, elevated 
glucagon levels, NME, and personal history of mul-
tiple endocrine neoplasia typ-1 (MEN) (10). 
Histologically, Kheir at al. (11) analyzed nine bi-
opsy specimens and distinguished five patterns of 
morphologic characteristics in NME: epidermal ne-
crosis (vacuolated, pale, and swollen epidermal cells), 
subcorneal pustules, psoriasiform pattern, angiopla-
sia or vascular dilatation of the papillary dermis, and 
suppurative folliculitis. Despite attempts to charac-
terize the histopathological features of NME, they still 
remain nonspecific, and epidermal necrosis of the 
upper spinous layer is considered the best diagnos-
tic sign. At the same time, its presence includes his-
tologic differential diagnosis such as zinc deficiency 
(acrodermatitis enteropathica), niacin deficiency (pel-
lagra), and NME (seen in chemotherapy settings) (12). 
The histopathology in our case was consistent with 
the above (11). On the other hand, histopathology of 
glucagonomas does not differ from other neuroen-
docrine tumors, but tumor cells of glucagonoma still 
show granulated abundant cytoplasm (13).
The pathogenesis of the disease is mainly due to 
the elevated level of serum glucagon that induces in-
flammatory mediators in the skin, which are responsi-
ble for epidermal necrosis. The evidence of this theory 
lies in the fact that surgical removal of glucagonomas 
or glucagonomas treated with a glucagon antago-
nist leads to resolution of the skin lesions. This was 
evident in our patient. Liver diseases can produce the 
same skin damage because of the decreased capacity 
of the liver to degrade glucagon. Zinc deficiency, pro-
tein deficiency, selective amino acid, or essential fatty 
acid deficiency may alter the metabolic pathway in 
the skin independently of glucagonoma, which also 
leads to clinical manifestation of NME (14).
Glucagonoma tends to grow slowly compared 
to non-islet cell pancreatic adenocarcinoma. Later in 
the course of the disease, glucagonoma metastasizes 
most commonly to the liver, followed by peripancre-
atic lymph nodes. Metastases are in fact the main neg-
ative prognostic factor for glucagonoma (4). Between 
50% and 90% of well-differentiated glucagonomas 
have metastasized by the time of diagnosis (15). Sur-
gical resection of the primary tumor is the definitive 
treatment for glucagonoma syndrome, although 
chemotherapeutic agents, somatostatin analogues, 
and radionuclide therapy are also employed (16). 
Figure 3. MRI of glucagonoma: the coronal T2-weighted 
image of the abdomen after IV-applied contrast, depicting 
the tumor mass as a high-intensity abnormality (3.0 cm × 2.5 
cm) in the tail of the pancreas, lying at the splenic hilum.
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CONCLUSION
The observed patient was diagnosed just in time, 
before metastases occurred. She underwent success-
ful surgery of a carcinoma with a subsequent long 
disease-free period. In general, most reported cases 
of glucagonoma are malignant, with many patients 
presenting with metastatic disease. That is why we 
believe our case is very instructive and could raise 
the awareness of the need for prompt recognition of 
NME, accurate diagnosis, and prevention of metasta-
ses of this tumor. In fact, the complete resection of 
the primary tumor offers the only chance of a cure. 
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